| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Protein synthesis initiation factor eIF4E. The 5' cap of eukaryotic mRNA, which consists of 7-methylguanosine (m7G) linked via a 5'-5' triphosphate bridge to the first transcribed nucleotide, is recognized by the eukaryotic translation initiation factor 4E (eIF4E). This interaction is a key regulatory step in the initiation of cap-dependent protein synthesis. m7GTP mimics the cap structure and acts as a competitive inhibitor, binding to eIF4E with high affinity and preventing the cap from binding, thereby blocking translation.
|
|---|---|
| ln Vitro |
m7GTP is a potent competitive inhibitor of cap-dependent translation. In cell-free translation systems such as rabbit reticulocyte lysate, m7GTP inhibits the translation of capped mRNA (e.g., luciferase or globin mRNA) with an IC50 in the low micromolar range. It binds to eIF4E with high affinity. It does not inhibit the translation of uncapped mRNAs (e.g., those with an internal ribosome entry site, IRES), demonstrating its specificity for cap-dependent translation.
|
| ln Vivo |
m7GTP is used to study the role of cap-dependent translation in cellular processes. It has been shown to reduce global protein synthesis in cell-based assays when delivered via permeabilization or electroporation. It is used to study the mechanisms of cap-independent translation driven by viral IRES elements. While not a therapeutic agent itself, m7GTP is a powerful research tool for dissecting the regulation of protein synthesis.
|
| Enzyme Assay |
m7GTP can be used in binding studies with purified eIF4E protein. Typically, fluorescence polarization (FP) or surface plasmon resonance (SPR) techniques are used to measure the binding affinity between m7GTP and eIF4E. In an FP assay, a fluorescently labeled cap analog (e.g., m7GTP-TAMRA) is incubated with recombinant eIF4E. Unlabeled m7GTP is added as a competitor, and the decrease in fluorescence polarization is measured to determine the binding affinity (Kd) of the interaction.
|
| Cell Assay |
m7GTP is not used in standard cell viability assays because it is not cell-permeable. For studies requiring translation inhibition, researchers often rely on cell-free systems. In a typical cell-free translation assay, rabbit reticulocyte lysate is mixed with a capped reporter mRNA (e.g., luciferase or GFP). Varying concentrations of m7GTP (0.1-100 uM) are added, and the reaction is incubated for 1 hour at 30degC. Translation efficiency is measured by quantifying the reporter protein activity (e.g., luminescence for luciferase) or by SDS-PAGE and autoradiography if [35S]-methionine is incorporated. The reduction in signal reflects cap-dependent translation inhibition.
|
| Animal Protocol |
For in vivo experiments, m7GTP is not used as a test article. However, if studying the role of eIF4E in an animal model of cancer, researchers might utilize m7GTP-Sepharose beads. In this case, tumor tissue is lysed, and the lysate is incubated with m7GTP-Sepharose beads to pulldown eIF4E and associated binding proteins (such as 4E-BP1). The bound proteins are then analyzed by Western blot to study the activity of the eIF4F translation initiation complex.
|
| ADME/Pharmacokinetics |
m7GTP sodium is soluble in water (H2O) and is typically stored as a concentrated stock solution at -20degC or -80degC. Molecular weight (free acid) is 537.21 g/mol. It is stable for several months when stored as a powder at -20degC, protected from light and moisture. The sodium salt form (m7GTP sodium) is used to improve aqueous solubility for biochemical assays.
|
| Toxicity/Toxicokinetics |
The toxicity of m7GTP is not extensively documented, as it is a research reagent and not a drug candidate. It is not toxic to cells at the concentrations used for in vitro biochemical assays (uM range). The compound is "For research use only" and is not intended for human therapeutic or diagnostic use.
|
| References | |
| Additional Infomation |
7-Methyl-guanosine-5'-triphosphate (m7GTP) is a research-grade biochemical tool used to study the biochemistry of mRNA translation. It is a nucleotide analog that functions as a competitive inhibitor of eIF4E. It is not a drug and has no FDA approval for human therapy. It is widely used in molecular biology to study cap-dependent translation and to assess the binding specificity of cap-binding proteins. Key references include Carberry et al. (1989) A spectroscopic study of the binding of m7GTP and m7GpppG to human protein synthesis initiation factor 4E.
|
| Molecular Formula |
C11H18N5O14P3.XNA
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~250 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
